Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer
"I am excited that Flamingo's approach to leveraging RNA for cancer drug development will be showcased at this important scientific meeting," commented Dr. Denker. "Long noncoding RNAs, part of the genetic 'dark matter', are gaining attention as potential novel targets in cancer and other diseases. The antisense oligonucleotide therapeutic modality is uniquely suited for lncRNA targets, and FLM-7523 is one of the most advanced therapeutics in development. We look forward to highlighting our approach at the AACR Special Conference."-Flamingo is developing two RNA therapies for cancer: danvatirsen, an antisense oligonucleotide in Phase 2 PEMDA-HN study, and FLM-7523, a MALAT1 inhibitor approaching Phase 1-
-Flamingo正在開發兩種抗癌RNA治療藥物：danvatirsen，一種參與第二階段PEMDA-HN研究的反義寡核苷酸，以及FLm-7523，一種即將進入第一階段的MALAT1抑制劑。
LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, Nov. 14, 2024 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") today announced an oral presentation at the AACR Special Conference in Cancer Research, RNAs as Drivers, Targets, and Therapeutics in Cancer, being held in Seattle, Washington from November 14-17, 2024.
比利時列uven，法國斯特拉斯堡和費城，2024年11月14日/美通社/-- Flamingo Therapeutics（"Flamingo"）今天宣佈將於2024年11月14日至17日在華盛頓州西雅圖舉行的"AACR特別會議：抗癌研究中的RNA作爲驅動因子、靶點和治療性藥物"上進行口頭報告。
Dr. Andrew Denker, Flamingo's Chief Medical Officer, will deliver an oral presentation on the Company's approach to developing RNA therapeutics against difficult-to-drug targets for cancer indications. Dr. Denker will discuss Flamingo's novel oligonucleotide targeting the long noncoding RNA (lncRNA) MALAT1, FLM-7523, discovered by Ionis Pharmaceuticals, which has recently completed IND-enabling preclinical activities and is moving toward a Phase 1 First-in-Human trial in solid tumors. Flamingo's lead program, danvatirsen, is an antisense oligonucleotide discovered by Ionis that selectively targets STAT3 mRNA and has shown clinical activity in HNSCC.
Flamingo的首席醫學官Andrew Denker博士將對公司在難以治療的靶點上開發RNA治療藥物的方法進行口頭報告。Denker博士將討論Flamingo的創新寡核苷酸，針對長鏈非編碼RNA（lncRNA）MALAT1的FLm-7523，該藥物由Ionis Pharmaceuticals發現，最近完成了IND促進前臨床活動，並將邁向固體腫瘤的第一階段首次人體試驗。Flamingo的主導項目danvatirsen是一種由Ionis發現的反義寡核苷酸，選擇性靶向STAT3 mRNA，並在頭頸部鱗狀細胞癌（HNSCC）中顯示出臨床活性。
"I am excited that Flamingo's approach to leveraging RNA for cancer drug development will be showcased at this important scientific meeting," commented Dr. Denker. "Long noncoding RNAs, part of the genetic 'dark matter', are gaining attention as potential novel targets in cancer and other diseases. The antisense oligonucleotide therapeutic modality is uniquely suited for lncRNA targets, and FLM-7523 is one of the most advanced therapeutics in development. We look forward to highlighting our approach at the AACR Special Conference."
「我很高興Flamingo在癌症藥物開發中利用RNA的方法將在這一重要科學會議上展示，」Denker博士評論道。「長鏈非編碼RNA作爲遺傳『暗物質』的一部分，正受到關注，作爲癌症和其他疾病的潛在新靶點。反義寡核苷酸治療模式特別適合lncRNA靶點，而FLm-7523是最先進的治療藥物之一。我們期待在AACR特別會議上突出我們的研究方法。」
Oral presentation details are as follows:
口頭報告的詳情如下：
Title: "Antisense Oligonucleotides as Therapeutics for Difficult-to-Drug Targets in Oncology"
Session Title: Plenary Session 6: Small RNA Therapeutics
Session Date and Time: Saturday, November 16, 2024, 3:30 pm
Presenting Author: Dr. Andrew Denker
標題：「反義寡核苷酸作爲腫瘤學中難以治療靶點的治療藥物」
會議標題：全體會議6：小型RNA治療藥物
會議日期和時間：2024年11月16日，星期六，下午3:30
報告作者：安德魯·登克博士
Abstracts selected for presentation during the meeting (poster or oral) will be published as a freely available supplement in an AACR journal on the first day of the meeting. For more information, please visit the AACR Special Conference 2024 website.
會議期間選定進行展示的摘要（海報或口頭）將在會議的第一天作爲免費補充刊登在AACR期刊上。有關更多信息，請訪問AACR特殊會議2024網站。
About Flamingo Therapeutics
關於Flamingo Therapeutics
Flamingo is pioneering RNA-targeted therapies for oncology with a clinical-stage pipeline targeting undruggable transcription factors and long non-coding RNAs. Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Abrdn (formerly funds managed by Tekla Capital Management LLC), Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, and VIB.
Flamingo正在爲腫瘤學開發針對RNA的療法，擁有一個臨床階段的管線，主要針對難以藥物化的轉錄因子和長非編碼RNA。Flamingo與Ionis Pharmaceuticals建立了合作關係，並得到了包括Abrdn（前身爲Tekla Capital Management LLC管理的基金）、Andera Partners、Bpifrance Large Venture、Bpifrance通過其FABS和Fonds Biothérapies Innovantes et Maladies Rares基金、Eurazeo - Kurma Partners、Perceptive Advisors、PMV、Pontifax、Sphera和VIb在內的知名生物技術投資者的支持。
Flamingo has initiated a Phase II trial 'PEMDA-HN' evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC). A Phase I investigator initiated trial study has also been initiated evaluating danvatirsen as a monotherapy and in combination with venetoclax in AML/MDS patients.
Flamingo已啓動一個II期臨床試驗'PEMDA-HN'，評估STAT3靶向藥物danvatirsen與pembrolizumab聯合應用於頭頸部鱗狀細胞癌（HNSCC）患者。還啓動了一個I期研究者發起的臨床試驗，評估以danvatirsen爲單藥治療和聯合使用venetoclax治療AML/MDS患者。
For more information on Flamingo, please visit:
有關Flamingo的更多信息，請訪問：
PEMDA-HN (head and neck cancer) on clinicaltrials.gov:
PEMDA-HN（頭頸癌）在clinicaltrials.gov上的信息：
Danvatirsen monotherapy followed by combination with venetoclax in relapsed/ refractory AML and MDS on clincaltrials.gov:
Danvatirsen單藥治療之後與venetoclax聯合治療復發/難治性AML和MDS在clinicaltrials.gov上的信息：
Please engage with us on LinkedIn:
.
請通過LinkedIn與我們互動：
.
Flamingo Media and Investor Contact:
Flamingo Media和投資者聯繫：
Amy Conrad
Juniper Point
(858) 366-3243
[email protected]
艾米·康拉德
墨杜拉角
(858) 366-3243
[email protected]
SOURCE Flamingo Therapeutics
來源：Flamingo Therapeutics
